Obinutuzumab (GA101) is a humanized IgG1 monoclonal antibody of Type II targeting CD20, currently under development for the treatment of non-Hodgkin lymphoma. This therapeutic antibody is designed to bind specifically to the CD20 antigen expressed on the surface of B cells, facilitating targeted immunotherapy with potential applications in oncological research and clinical practice.
Obinutuzumab (GA101) is a humanized IgG1 monoclonal antibody of Type II targeting CD20, currently under development for the treatment of non-Hodgkin lymphoma. This therapeutic antibody is designed to bind specifically to the CD20 antigen expressed on the surface of B cells, facilitating targeted immunotherapy with potential applications in oncological research and clinical practice.
Product Information
Catalog Num
AT1332
Molecular Weight
146320
CAS Number
949142-50-1
Isotype
Human IgG1 kappa, Isotype Control
Species
Humanized
Synonyms
GA101; Anti-Human CD20 type II, Humanized Antibody
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
